Original InvestigationMorphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The EARLY ACS trial received grant funding from Schering-Plough. The work of Dr. Furtado was supported by the Lemann Foundation Cardiovascular Research Postdoctoral Fellowship, Harvard University/Brigham and Women’s Hospital. The current analyses received no sources of external funding. Dr. Furtado has received honoraria from AstraZeneca; and has received research grants from AstraZeneca, DalCor, Boehringer Ingelheim, Pfizer, Bayer, and Sanofi. Dr. Nicolau has received research grants from Amgen Inc., Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb Company, CLS Behring, DalCor, Janssen Pharmaceuticals Inc., Novartis, Population Research Institute, Novo Nordisk, Sanofi, and AstraZeneca; and has served as a consultant/on the advisory board for Bayer, Daiichi-Sankyo, Novartis, Servier, and Sanofi. Dr. Guo has received research grants from Merck. Dr. Im has received research grants from Merck; and is a member of the Thrombosis In Myocardial Infarction Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals Incl., BRAHMS, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zora Biosciences. Dr. Sabatine has received research grant support through Brigham and Women’s Hospital from Abbott Laboratories, Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Eisai, Gilead, GlaxoSmithKline, Intarcia, Janssen Research and Development, The Medicines Company, MedImmune, Merck, Novartis, Poxel, Pfizer, Quark Pharmaceuticals, Roche Diagnostics, and Takeda; is a member of the Thrombosis In Myocardial Infarction Study Group, which has also received institutional research grant support through Brigham and Women’s Hospital from Abbott, Aralez, Roche, and Zora Biosciences; and has received consulting fees from Alnylam, Amgen, AstraZeneca, Bristol-Myers Squibb, CVS Caremark, DalCor, Dyrnamix, Esperion, IFM Therapeutics, Intarcia, Ionis, Janssen Research and Development, The Medicines Company, MedImmune, Merck, MyoKardia, and Novartis. Dr. Newby has received a research grant from Boehringer Ingelheim; and has served as a consultant/on the advisory board for Roche Diagnostics, Ortho-Clinical Diagnostics, Quidel, BioKier, Bristol-Myers Squibb, and CSL. Dr. Giugliano has received research grants from Amgen, Daiichi-Sankyo, and Merck; has received honoraria from Amgen, Daiichi-Sankyo, and Merck; has provided CME lectures for Amgen, Daiichi-Sankyo, Merck, and Servier; and has served as a consultant/on the advisory board for Akcea, Amarin, American College of Cardiology, Amgen, Angel Med, Beckman-Coulter, Boehringer Ingelheim, Bristol-Myers Squibb, CVS Caremark, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Lexicon, Merck, Portola, Pfizer, St. Jude, and Stealth Peptides. Ms. White has reported that she has no relationships relevant to the contents of this paper to disclose.